designation of the baseline
quarter for AMP and CPI-U
is contingent upon the market
entry date of the product. Drugs
brought to market prior to
April 1, 2013 will use the third
quarter of 2014, while drugs
introduced after this date will
use the fifth full calendar quarter
after the market entry date. 2, 3
The first consideration for
generic drug manufacturers
will be which products fall
on either side of the April 1,
2013 threshold, based on their
market entry dates. After this
point, the corresponding values
for Baseline AMP and CPI-U
should be retrieved so that
data can be prepared for the
amendment's effective date, and
sample calculations executed.
Finally, manufacturers will want
to determine whether the results
of these calculations necessitate a
restatement for AMP, particularly
since either Baseline AMP (3Q
2014 or 5th full quarter) is
currently within the three-year
window for restatements.
manufacturers employ a Revenue
Management System (RMS)
designed to operate under
specific parameters given the
current governmental landscape.
Generic drug manufacturers will
need to determine the ease in
which a change to the Medicaid
URA formula in these systems
Responsive by Design.
CustomVault is your solution for
customized vault systems and complementary security.
Full compliance with security regulations is essential to
your success, but not all sites are the same. Your
solution has to be as unique as you are. CustomVault
delivers collaborative design and professional
attention from project inception to completion.
And with over 30 years of experience and leadership in
DEA validated solutions, we can ensure the best result
to meet all of your current needs and accommodate
your plans for the future.